Jan 4 (Reuters) - Audentes Therapeutics Inc:
* AUDENTES ANNOUNCES POSITIVE INTERIM DATA FROM FIRST DOSE COHORT OF ASPIRO, A PHASE 1/2 CLINICAL TRIAL OF AT132 IN PATIENTS WITH X-LINKED MYOTUBULAR MYOPATHY
* PLANS TO PROVIDE NEXT UPDATE ON INTERIM DATA FROM ASPIRO IN Q2 2018
* TOTAL 6 ADVERSE EVENTS (AES) REPORTED IN ASPIRO, 2 OF WHICH WERE DETERMINED TO BE SERIOUS ADVERSE EVENTS (SAES)
* OF FOUR NON-SERIOUS ADVERSE EVENTS, TWO HAVE BEEN DETERMINED TO BE PROBABLY OR POSSIBLY TREATMENT-RELATED
* AUDENTES PLANS TO PROVIDE NEXT UPDATE ON INTERIM DATA FROM ASPIRO IN Q2 OF 2018 Source text for Eikon: Further company coverage:
